2023 Targeted Therapies of Lung Cancer Meeting (Poster)-P1.02. MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer (NSCLC): An Analysis by Specific Mutation, Histology, and Smoking Status

P1.02. MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer (NSCLC): An Analysis by Specific Mutation, Histology, and Smoking Status

Back to course

Pdf Summary

The document discusses the heterogeneity of MET exon 14 skipping mutations (METex14) in non-small cell lung cancer (NSCLC) based on specific mutations, histology, and smoking status. MET is a gene that plays a role in cell proliferation and survival, and mutations in exon 14 can lead to skipping of the Y1003 loci, which is important for regulating MET activation. METex14 mutations are now considered therapeutic targets in NSCLC. <br /><br />The study found that there is significant heterogeneity within METex14 NSCLC, with differences in co-mutations, tumor mutational burden (TMB), and PD-L1 expression among different METex14 mutations. The presence of these mutations was observed in both squamous and non-squamous NSCLC, but there were differences in the enrichment of oncogenic pathways, which may explain the varying response to treatments. Further studies on specific METex14 alterations could help personalize treatment for patients with METex14 NSCLC.<br /><br />Smoking status data was available for 93 METex14 cases. Those with a history of smoking were enriched in certain subtypes of METex14 mutations. Additionally, there were differences in HLA-G mRNA expression and pathway activation between smokers and non-smokers with METex14 NSCLC.<br /><br />The document provides information on the methodology used, including DNA and RNA sequencing techniques, as well as the analysis of co-mutations, PD-L1 expression, and TMB. Figures and tables present data on specific mutations, histology, and smoking status in METex14 NSCLC cases.<br /><br />In conclusion, the study highlights the heterogeneity of METex14 mutations in NSCLC and the importance of considering specific mutation types, histology, and smoking status in personalized treatment approaches. Further research is needed to better understand the implications of these differences in order to optimize treatment strategies for patients with METex14 NSCLC.

Asset Subtitle

Jennifer A. Marks, Georgetown University, United States

Meta Tag

Speaker Jennifer A. Marks, Georgetown University, United States

Topic Poster Listing

Keywords

MET exon 14 skipping mutations

non-small cell lung cancer

specific mutations

histology

smoking status

MET gene

cell proliferation

MET activation

therapeutic targets

co-mutations